|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Arrowhead Reports Fiscal 2015 Third Quarter Financial Results
- Conference Call and Webcast Today at 4:30 p.m. EDT
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2015 third quarter ended June 30, 2015. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadresearch.com/events.cfm. For analysts that wish to participate in the conference call, please dial 315-625-6887 and enter Conference ID 97375077.
A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 404-537-3406 and enter Conference ID 97375077.
Fiscal 2015 Third Quarter and Recent Company Highlights
ARC-520
Received regulatory permission to initiate three multiple-dose Phase 2b studies in the United States (Heparc-2004) and in Germany and Hong Kong (Heparc-2002 and 2003)
Completed dosing of four cohorts in a single-dose Phase 2a study (Heparc-2001) and expanded the study to include three additional cohorts
Completed dosing in a non-clinical study in chronically infected chimpanzees that spanned more than a year
Highlights of the Phase 2a and chimpanzee studies to be presented at an analyst day planned for September 24, 2015
ARC-AAT
Met the dosing target for Part A of the ARC-AAT Phase 1 study in healthy volunteers, and transitioned the study into Part B which is designed to enroll patients with PiZZ genotype alpha-1 antitrypsin deficiency
Began dosing Part B of the Phase 1 study at one site in Australia
Gained regulatory clearance to expand Part B of the Phase 1 study to allow additional sites in the United Kingdom and New Zealand
Gained Orphan Drug Designation from the United States Food and Drug Administration
Platform and Early Pipeline
Published data on advances being made in a subcutaneously administered formulation of the Dynamic Polyconjugate (DPC) delivery system
Presented preclinical data on ARC-F12, a potential new candidate targeting coagulation factor 12 for the potential treatment of hereditary angioedema and thromboembolic diseases
Selected Fiscal 2015 Third Quarter Financial Results
ARROWHEAD RESEARCH CORPORATION
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)
Three Months Ended June 30, Nine Months Ended June 30,
OPERATING SUMMARY
2015 2014 2015 2014
REVENUE $ 123,750
$
43,750
$ 338,250 $ $131,250
OPERATING EXPENSES
Research and development 7,490,400 6,392,200 36,877,925 14,719,739
Acquired in-process research and development - - 10,142,786 -
Salaries and payroll-related costs 3,570,531 2,454,449 10,262,799 7,634,142
General and administrative expenses 1,829,393 1,582,465 5,612,219 3,865,845
Stock-based compensation 2,486,074 2,038,682 6,706,009 3,758,264
Depreciation and amortization 741,058 276,054 1,480,656 1,075,238
TOTAL OPERATING EXPENSES 16,117,456 12,743,850 71,082,394 31,053,228
OPERATING LOSS (15,993,706 ) (12,700,100 ) (70,744,144 ) (30,921,978 )
OTHER INCOME/(EXPENSE) 57,653 1,073,649
3,546,398 (5,372,902 )
NET LOSS $ (15,936,053 ) $ (11,626,451 ) $ (67,197,746 ) $ (36,294,880 )
EARNINGS PER SHARE (BASIC AND DILUTED): $ (0.27 ) $ (0.22 ) $ (1.19 ) $ (0.81 )
WEIGHTED AVERAGE SHARES OUTSTANDING 59,492,867 51,931,989 56,631,297 44,565,008
FINANCIAL POSITION SUMMARY
June 30, March 31,
2015 2015
CASH AND CASH EQUIVALENTS $ 87,252,813 $ 96,447,301
SHORT AND LONG-TERM INVESTMENTS 24,365,922 31,922,240
TOTAL CASH RESOURCES (CASH, CASH EQUIVALENTS, INVESTMENTS) 111,618,735 128,369,541
OTHER ASSETS 33,571,590 34,008,917
TOTAL ASSETS $ 145,190,325 $ 162,378,458
TOTAL LIABILITIES $ 14,445,931 $ 18,182,104
TOTAL STOCKHOLDERS' EQUITY 130,744,394 144,196,354
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 145,190,325 $ 162,378,458
SHARES OUTSTANDING 59,498,362 59,435,862
PROFORMA SHARES OUTSTANDING (INCLUDING CONVERSION OF PREFERRED SHARES) 62,169,352 62,106,852
About ARC-520
Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically, to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. Arrowhead has completed a Phase 1 single ascending dose study in normal volunteers and the company is conducting single dose Phase 2a studies and multiple dose Phase 2b studies in chronic HBV patients. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally.
About ARC-AAT
Arrowhead's ARC-AAT is being investigated for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease that severely damages the liver and lungs of affected individuals. The mean estimated prevalence of AATD in the U.S. is 1 per 3000-5000, or approximately 100,000 patients. AATD is also an important cause of pediatric liver disease with an estimated prevalence in children of approximately 20,000 patients, and 50-80% likely to manifest liver disease during childhood. It is a rare disease that appears to be frequently misdiagnosed or undiagnosed. ARC-AAT, which was granted orphan drug designation, employs a novel unlocked nucleobase analog (UNA) containing RNAi trigger molecule designed for systemic delivery using the Dynamic Polyconjugate™ delivery system. ARC-AAT is highly effective at knocking down the Alpha-1 antitrypsin (AAT) gene transcript and reducing the hepatic production of the mutant AAT (Z-AAT) protein in animal models. Reduction of liver production of the inflammatory Z-AAT protein, which is believed to be the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease and potentially allow fibrotic tissue repair. Arrowhead is conducting a single dose Phase 1 clinical study of ARC-AAT, with part A in healthy volunteers and part B in AATD patients |
|
楼主: crystalandtiger
发表于 2015-8-4 22:20
